Skip to content

clinical and pre clinical stuy of Sameera pannaga rasa in Tamaka shwasa management

Genotoxicity study of Sameera Pannaga Rasa and itâ??s efficacy in the management of Tamaka Shwasa (Bronchial Asthma)

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017844
Enrollment
50
Registered
2019-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: Sameera Pannaga Rasa: Dose 62.5 mg two times in a day Duration 60 days Route of administration oral Indication Tamaka Shwasa Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Sponsors

IPGT AND RA GAU JAMNAGAR GUJARAT
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients presenting with classical signs and symptoms of Tamaka Shwasa 29, 30 2 Both the sexes having age between 18 years to 60 years 3 Mild persistent cases of Bronchial Asthma (Episodes of wheezing, coughing, or shortness of breath that occur more than twice a week but less than once a day, symptoms usually occur at least twice a month at night, may affect normal physical activity) 4 Moderate persistence cases (it is considered if without treatment any of the following are true; symptoms occur daily more than one-night attack per week. Inhaled short acting asthma medication is used every day. Symptoms interfere with daily activities.)

Exclusion criteria

Exclusion criteria: 1 Known patients of diabetes and uncontrolled systemic arterial hypertension. 2 Dyspnea resulting from cardiac origin, severe anemia with Hb% of 6. 3 Age above 60 years and below 18 years, 4 Patients suffering from tuberculosis, malignancy and other chronic debilitating diseases, COPD, Emphysema, upper respiratory tract obstruction, bronchiectasis, Interstitial lung disease, occupational lung disease, tropical pulmonary eosinophilia, active pulmonary Tuberculosis, Pulmonary malignancy, chronic pleuritis, plural effusion, lower respiratory tract infection or systemic infection). 5 Pregnant and lactating mothers 6 Patients suffering with other types of Shwasa, i.e. Maha, Urdhva, Chhinna Shwasa will be excluded from the study. 7 Febrile patients on presentation or history of fever within past one week.

Design outcomes

Primary

MeasureTime frame
Assessment of relief from Tamaka Shwasa will be done on the basis of clinical sign and symptoms with laboratory investigationsTimepoint: 60 days

Secondary

MeasureTime frame
decrease severityTimepoint: 60 days

Countries

India

Contacts

Public ContactDr BJ patgiri

INSTITUTE OF POST GRADUATE TEACHING AND RESEARCH IN AYURVEDA

patgiri124@gmail.com9426947438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026